CARB-X funds work on novel antibiotic for carbapenem-resistant pathogensCARB-X announced today that it is awarding up to $6.4 million to French biopharmaceutical firm Mutabilis to develop a new class of antibiotics to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.The award from CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) will help fund the preclinical development of EBL-1463, a potential first in-class representative of the dabocin family.
The compound is a non-beta-lactam inhibitor of penicillin-binding proteins that kills bacteria by interfering with cell wall synthesis.